A few days ago my trading partner Ilene suggested that we add Discovery Laboratories (DSCO) to the Avian Flu Basket.
Ilene's analysis was based on her reasoning that DSCO might be serendipidously involved in the development of a drug, Surfaxin, that could be used in the treatment of Acute Respiratory Distress Syndrome("ARDS"), a condition, often fatal, that may be caused by bird flu. If it is found that Surfaxin is effective in ARDS, then it should similarly be useful to treat avian flu. DSCO is currently engaged in a clinical trial using Surfaxin for ARDS (caused by other insults to the lung besides avian flu infection).
We posted our thoughts on Silicon Investor and on the Yahoo message board for DSCO, looking for some feedback from others who follow the company. Our efforts have paid off, as based on what we have uncovered in the past few days, we are adding DSCO to our Avian Flu Basket.
Here is a link to Ilene's original post on Yahoo and a series of outstanding responses from some very informed individuals, the final three of which simply hit the ball out of the park on this one:
DSCO & Bird Flu
This brings to ten the number of stocks on our Avian Flu Basket.